Human Oncology & Pathogenesis Program
The Katharine Hsu Lab
My laboratory studies the natural killer (NK) cell and the molecules that control its ability to recognize and kill cancer and virally infected cells. Improved understanding of how NK cells behave is critical to advancing our ability to harness their innate capacity for tumor recognition and eradication. Therefore, an important component of my research focuses on the basic biology of the NK cell, identifying the molecules involved in controlling NK reactivity, and determining the laboratory and clinical conditions under which NK activity can be modified.
Wu Z, Park S, Lau CM, Zhong Y, Sheppard S, Sun JC, Das J, Altan-Bonnet G, Hsu KC. Dynamic variability in SHP-1 abundance determines natural killer cell responsiveness. Sci Signal. 2021 Nov 9;14(708):eabe5380. doi: 10.1126/scisignal.abe5380. Epub 2021 Nov 9.
Wu Z, Lau CM, Sottile R, Le Luduec JB, Panjwani MK, Conaty PM, Srpan K, Laib Sampaio K, Mertens T, Adler SP, Hill AB, Barker JN, Cheung NV, Sun JC, Hsu KC. Human Cytomegalovirus Infection Promotes Expansion of a Functionally Superior Cytoplasmic CD3+ NK Cell Subset with a Bcl11b-Regulated T Cell Signature. J Immunol. 2021 Nov 15;207(10):2534-2544. doi: 10.4049/jimmunol.2001319. Epub 2021 Oct 8. PMCID: PMC8578400.
Sottile R, Panjwani MK, Lau CM, Daniyan AF, Tanaka K, Barker JN, Brentjens RJ, Sun JC, Le Luduec JB, Hsu KC. Human cytomegalovirus expands a CD8+ T cell population with loss of BCL11B expression and gain of NK cell identity. Sci Immunol. 2021 Sep 24;6(63):eabe6968. doi: 10.1126/sciimmunol.abe6968. Epub 2021 Sep 24.
Schetelig J, Baldauf H, Koster L, Kuxhausen M, Heidenreich F, de Wreede LC, Spellman S, van Gelder M, Bruno B, Onida F, Lange V, Massalski C, Potter V, Ljungman P, Schaap N, Hayden P, Lee SJ, Kröger N, Hsu K, Schmidt AH, Yakoub-Agha I, Robin M. Haplotype Motif-Based Models for KIR-Genotype Informed Selection of Hematopoietic Cell Donors Fail to Predict Outcome of Patients With Myelodysplastic Syndromes or Secondary Acute Myeloid Leukemia. Front Immunol. 2021 Jan 19;11:584520. doi: 10.3389/fimmu.2020.584520. PMCID: PMC7851088.
Boudreau JE, Giglio F, Gooley TA, Stevenson PA, Le Luduec JB, Shaffer BC, Rajalingam R, Hou L, Hurley CK, Noreen H, Reed EF, Yu N, Vierra-Green C, Haagenson MD, Malkki M, Petersdorf EW, Spellman S, Hsu KC. KIR3DL1/HLA-B subtypes govern AML relapse after hematopoietic cell transplantation. J Clin Onc. 2017. 35(20):2268-2278.
Katharine C. Hsu, MD, PhD
Professor of Medicine
- Physician-scientist Katharine Hsu studies the biology of human natural killer cells and how they contribute to disease processes.
- MD, PhD, Cornell University Medical College
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Katharine C. Hsu discloses the following relationships and financial interests:
Professional Services and Activities (Uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.